Bio markers in Gastroenterology

Gastrointestinal cancers account for approximately 25% of all cancer deaths in the Western world. There is a basic preventive approach that can utilize biomarkers in order to stratify patients into appropriate screening or surveillance programs. Biomarkers are clinical variables associated with clinical outcomes. In cancer biology, the best biomarkers are germline adenomatous polyposis coli mutations, which are highly predictive of colon cancer. In other areas, such as Barrett’s esophagus, despite early excellent success in identifying the importance of p16, p53, and aneuploidy in esophageal adenocarcinoma pathogenesis, useful biomarkers are still not widely used in clinical practice. New molecular biomarkers are identified in the future like epigenetic methylation patterns and genetic polymorphisms. In the meantime, clinicians must trust on healthy, inexpensive methods such as standard histopathology. Dysplasia is still the mainstay of cancer prediction in most inflammatory disorders of the GI tract and is an independent marker of cancer risk.

 

    Related Conference of Bio markers in Gastroenterology

    April 24-25, 2019

    International Conference on Gastroenterology and Hepatology

    Novotel Budapest City, Budapest, Hungary.
    April 24-25, 2019

    International conference on Liver and Hepatitis

    Novotel Budapest City, Budapest, Hungary
    July 08-09-2019

    14th Euro-Global Gastroenterology Conference

    Zurich, Switzerland
    July 15-16, 2019

    7th International Conference on Hepatology

    Sydney, Australia
    September 23-24, 2019

    2nd World Summit on Liver Cirrhosis and Hepatitis

    Tokyo, Japan
    October 14-15, 2019

    19th World Gastroenterologists Summit

    Sydney, Australia
    October 23-24, 2019 |

    World Congress on Pancreatic Cancer and Liver Diseases

    Tokyo, Japan

    Bio markers in Gastroenterology Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in